Nima Gharahdaghi
Pharmacological hypogonadism impairs molecular transducers of exercise-induced muscle growth in humans
Gharahdaghi, Nima; Rudrappa, Supreeth; Brook, Matthew S.; Farrash, Wesam; Idris, Iskandar; Aziz, Muhammad Hariz Abdul; Kadi, Fawzi; Papaioannou, Konstantinos; Phillips, Bethan E.; Sian, Tanvir; Herrod, Philip J.; Wilkinson, Daniel J.; Szewczyk, Nathaniel J.; Smith, Kenneth; Atherton, Philip J.
Authors
Supreeth Rudrappa
Mr MATTHEW BROOK MATTHEW.BROOK@NOTTINGHAM.AC.UK
Associate Professor
Wesam Farrash
Professor ISKANDAR IDRIS Iskandar.Idris@nottingham.ac.uk
PROFESSOR OF DIABETES AND METABOLIC MEDICINE
Muhammad Hariz Abdul Aziz
Fawzi Kadi
Konstantinos Papaioannou
Professor BETH PHILLIPS beth.phillips@nottingham.ac.uk
PROFESSOR OF TRANSLATIONAL PHYSIOLOGY
Tanvir Sian
Philip J. Herrod
Dr DANIEL WILKINSON DANIEL.WILKINSON@NOTTINGHAM.AC.UK
PRINCIPAL RESEARCH FELLOW
Nathaniel J. Szewczyk
Professor KENNETH SMITH KEN.SMITH@NOTTINGHAM.AC.UK
PROFESSOR OF METABOLIC MASS SPECTROMETRY
Philip J. Atherton
Abstract
Background: The relative role of skeletal muscle mechano-transduction in comparison with systemic hormones, such as testosterone (T), in regulating hypertrophic responses to exercise is contentious. We investigated the mechanistic effects of chemical endogenous T depletion adjuvant to 6weeks of resistance exercise training (RET) on muscle mass, function, myogenic regulatory factors, and muscle anabolic signalling in younger men. Methods: Non-hypogonadal men (n=16; 18–30years) were randomized in a double-blinded fashion to receive placebo (P, saline n=8) or the GnRH analogue, Goserelin [Zoladex (Z), 3.6mg, n=8], injections, before 6weeks of supervised whole-body RET. Participants underwent dual-energy X-ray absorptiometry (DXA), ultrasound of m. vastus lateralis (VL), and VL biopsies for assessment of cumulative muscle protein synthesis (MPS), myogenic gene expression, and anabolic signalling pathway responses. Results: Zoladex suppressed endogenous T to within the hypogonadal range and was well tolerated; suppression was associated with blunted fat free mass [Z: 55.4±2.8 to 55.8±3.1kg, P=0.61 vs. P: 55.9±1.7 to 57.4±1.7kg, P=0.006, effect size (ES)=0.31], composite strength (Z: 40±2.3% vs. P: 49.8±3.3%, P=0.03, ES=1.4), and muscle thickness (Z: 2.7±0.4 to 2.69±0.36cm, P>0.99 vs. P: 2.74±0.32 to 2.91±0.32cm, P<0.0001, ES=0.48) gains. Hypogonadism attenuated molecular transducers of muscle growth related to T metabolism (e.g. androgen receptor: Z: 1.2 fold, P>0.99 vs. P: 1.9 fold, P<0.0001, ES=0.85), anabolism/myogenesis (e.g. IGF-1Ea: Z: 1.9 fold, P=0.5 vs. P: 3.3 fold, P=0.0005, ES=0.72; IGF-1Ec: Z: 2 fold, P>0.99 vs. P: 4.7 fold, P=0.0005, ES=0.68; myogenin: Z: 1.3 fold, P>0.99 vs. P: 2.7 fold, P=0.002, ES=0.72), RNA/DNA (Z: 0.47±0.03 to 0.53±0.03, P=0.31 vs. P: 0.50±0.01 to 0.64±0.04, P=0.003, ES=0.72), and RNA/ASP (Z: 5.8±0.4 to 6.8±0.5, P>0.99 vs. P: 6.5±0.2 to 8.9±1.1, P=0.008, ES=0.63) ratios, as well as acute RET-induced phosphorylation of growth signalling proteins (e.g. AKTser473: Z: 2.74±0.6, P=0.2 vs. P: 5.5±1.1 fold change, P<0.001, ES=0.54 and mTORC1ser2448: Z: 1.9±0.8, P>0.99 vs. P: 3.6±1 fold change, P=0.002, ES=0.53). Both MPS (Z: 1.45±0.11 to 1.50±0.06%·day−1, P=0.99 vs. P: 1.5±0.12 to 2.0±0.15%·day−1, P=0.01, ES=0.97) and (extrapolated) muscle protein breakdown (Z: 93.16±7.8 vs. P: 129.1±13.8g·day−1, P=0.04, ES=0.92) were reduced with hypogonadism result in lower net protein turnover (3.9±1.1 vs. 1.2±1.1g·day−1, P=0.04, ES=0.95). Conclusions: We conclude that endogenous T sufficiency has a central role in the up-regulation of molecular transducers of RET-induced muscle hypertrophy in humans that cannot be overcome by muscle mechano-transduction alone.
Citation
Gharahdaghi, N., Rudrappa, S., Brook, M. S., Farrash, W., Idris, I., Aziz, M. H. A., Kadi, F., Papaioannou, K., Phillips, B. E., Sian, T., Herrod, P. J., Wilkinson, D. J., Szewczyk, N. J., Smith, K., & Atherton, P. J. (2022). Pharmacological hypogonadism impairs molecular transducers of exercise-induced muscle growth in humans. Journal of Cachexia, Sarcopenia and Muscle, 13(2), 1134-1150. https://doi.org/10.1002/jcsm.12843
Journal Article Type | Article |
---|---|
Acceptance Date | Sep 30, 2021 |
Online Publication Date | Mar 1, 2022 |
Publication Date | Apr 1, 2022 |
Deposit Date | Mar 4, 2022 |
Publicly Available Date | Mar 4, 2022 |
Journal | Journal of Cachexia, Sarcopenia and Muscle |
Print ISSN | 2190-5991 |
Electronic ISSN | 2190-6009 |
Publisher | Wiley Open Access |
Peer Reviewed | Peer Reviewed |
Volume | 13 |
Issue | 2 |
Pages | 1134-1150 |
DOI | https://doi.org/10.1002/jcsm.12843 |
Keywords | Physiology (medical); Orthopedics and Sports Medicine |
Public URL | https://nottingham-repository.worktribe.com/output/7536568 |
Publisher URL | https://onlinelibrary.wiley.com/doi/10.1002/jcsm.12843 |
Files
Pharmacological hypogonadism impairs molecular transducers of exercise-induced muscle growth in humans
(1.9 Mb)
PDF
Publisher Licence URL
https://creativecommons.org/licenses/by/4.0/
You might also like
Deuterium brain imaging at 7T during D2O dosing
(2022)
Journal Article
Downloadable Citations
About Repository@Nottingham
Administrator e-mail: discovery-access-systems@nottingham.ac.uk
This application uses the following open-source libraries:
SheetJS Community Edition
Apache License Version 2.0 (http://www.apache.org/licenses/)
PDF.js
Apache License Version 2.0 (http://www.apache.org/licenses/)
Font Awesome
SIL OFL 1.1 (http://scripts.sil.org/OFL)
MIT License (http://opensource.org/licenses/mit-license.html)
CC BY 3.0 ( http://creativecommons.org/licenses/by/3.0/)
Powered by Worktribe © 2025
Advanced Search